Eurofins (Paris:ERF):
- Before the annual meeting of 300 of its Business Unit leaders on 26 January 2021, Eurofins pre-announces some of its 2020 results.
- December 2020 trading performance has been strong in both our core business (excluding COVID-19 clinical reagents and testing revenues) and in our COVID related activities, building further on October and November’s momentum.
- Eurofins achieved FY 2020 Revenues of over EUR 5.4bn 1 (up from the most recent EUR 5.3bn objective and the original target of EUR 5.0bn).
- Q4 2020 organic growth was close to 40% 1 .
- FY 2020 organic growth was close to 20% 1 .
- Q4 2020 organic growth rate of our core business (excluding COVID-19 clinical reagents and testing revenues) of 5% 1 2 ; and
- Positive organic growth of our core business in FY 2020 1 2 .
To learn more, please visit https://www.eurofins.com/media-centre/press-releases/2021-01-25/
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
___________________
1 These management estimates have not yet been subject to an audit
2 Excluding COVID related activities
View source version on businesswire.com: https://www.businesswire.com/news/home/20210124005085/en/
Contacts
Investor Relations
ir@eurofins.com
The post Eurofins Achieved Revenues in Excess of EUR 5.4bn in 2020, After Continued Momentum in December Across Both Its Core Business and COVID-19 Related Activities first appeared on Financial Buzz .
For further details see:
Eurofins Achieved Revenues in Excess of EUR 5.4bn in 2020, After Continued Momentum in December Across Both Its Core Business and COVID-19 Related Activities